ZMapp

ZMapp (pronounced: zee-map) is an experimental biopharmaceutical drug that was developed by Mapp Biopharmaceutical for the treatment of Ebola virus disease.

Pronunciation

The term ZMapp is pronounced as "zee-map".

Etymology

The name "ZMapp" is derived from the initials of the company that developed it, Mapp Biopharmaceutical, with the 'Z' possibly referring to the Zaire strain of the Ebola virus, against which the drug was primarily designed.

Development

ZMapp was developed using a process called "phage display". This process involves the use of bacteriophages - viruses that infect bacteria - to create new proteins. The drug is a combination of three different monoclonal antibodies that bind to the protein of the Ebola virus.

Usage

ZMapp is used in the treatment of Ebola virus disease. It was first used in humans during the 2014-2016 Ebola outbreak in West Africa. However, it is still considered experimental as it has not yet been fully tested for safety or efficacy in humans.

Related Terms

• Ebola virus disease
• Monoclonal antibodies
• Bacteriophages
• Phage display
• Mapp Biopharmaceutical

See Also

• List of Ebola outbreaks
• Ebola virus cases in the United States
• Ebola virus epidemic in Sierra Leone

External links

• Medical encyclopedia article on ZMapp
• Wikipedia's article - ZMapp

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski